Core Insights - Global drugmakers are intensifying their search for China-developed experimental medicines as they aim to cut costs ahead of patent expirations, with predictions of a record surge in licensing deals this year [1][2] Licensing Deal Value - The value of licensing deals in the greater China region rose nearly tenfold from 2021 to an unprecedented $137.7 billion last year, with mainland China being the focal point for global drugmakers [2] - The total value of licensing-out deals is expected to double again over the next 18-24 months, driven by a strong focus on innovative drug pipelines in China [3] Growth Predictions - Analysts predict a cautious growth of 40%-50% in licensing deals this year, particularly for drugs considered essential for oncological treatments [3] Deal Structures - Licensing agreements allow companies to develop, manufacture, or commercialize pharmaceutical products in exchange for upfront fees or milestone payments, thus reducing development risks [4] Surge in Deal Sizes - The average deal size has reached $1.3 billion this year, a 76% increase from 2025 levels and approximately six times the average in 2021, largely due to significant deals like AstraZeneca's $18.5 billion agreement and AbbVie's $5.6 billion deal [5] - In 2026, 38 out-licensing deals have already been announced, following a total of 186 deals signed last year [6] Specific Licensing Agreements - Madrigal Pharmaceuticals announced a licensing deal with Suzhou Ribo Life Science for experimental liver-disease programs, involving an upfront payment of $60 million and potential total payments of up to $4.4 billion [7]

Core Viewpoint - Novavax has experienced a significant decline in market value over the past five years, losing more than 90% despite successfully launching a coronavirus vaccine later than expected, which has affected its competitiveness in the market [1] Group 1: Recent Developments - Novavax's shares have increased by 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology [2] - The licensing agreement with Pfizer includes an upfront payment of $30 million, potential milestone payments of up to $500 million, and royalties on future approved products utilizing the adjuvant technology [3] - This is not the first licensing deal for Novavax's Matrix-M platform, as Sanofi also entered a similar agreement two years prior [4] Group 2: Revenue and Market Challenges - Novavax's revenue has been inconsistent, and changes in U.S. regulatory recommendations regarding coronavirus vaccine eligibility may hinder future sales [5] - Sanofi will lead commercialization efforts for Novavax's vaccine in the U.S. and other markets, with Novavax receiving royalties on sales, but the revenue outlook remains uncertain [6] - The market for coronavirus vaccines is unpredictable, and Novavax's financial success may depend on the performance of pipeline products from Pfizer or Sanofi that utilize its adjuvant technology [7] Group 3: Internal Developments - Novavax is also working on developing several vaccines internally, including a flu vaccine and a combination coronavirus/flu vaccine [8] - Phase 3 studies for these candidates were placed on clinical hold in October 2024 due to suspected adverse reactions, which has delayed progress despite the hold being lifted [8]